Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma

Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-01, Vol.15 (1), p.e33538
Main Authors: Azad, Farhan, Moyer, Ross, Miranda, Clive J, Gravina, Matthew
Format: Article
Language:English
Subjects:
Blood tests
Carbon dioxide
Cardiology
Case reports
Chemotherapy
Creatinine
Ejection fraction
Emergency medical care
Heart failure
Hemoglobin
Inhibitor drugs
Laboratories
Medical prognosis
Metabolism
Multiple myeloma
Oncology
Patients
Potassium
Targeted cancer therapy
Tomography
Ultrasonic imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c266t-9e57138db65372853008f6f02d5699c30f8c7d6c654c6cee6d865cd87da93d7a3
container_end_page
container_issue 1
container_start_page e33538
container_title Curēus (Palo Alto, CA)
container_volume 15
creator Azad, Farhan
Moyer, Ross
Miranda, Clive J
Gravina, Matthew
description Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following the use of PIs in MM, a malignancy not known to cause TLS, has seldom been reported. We present a case of a patient with a known diagnosis of MM who received prior therapy including bortezomib, a first-generation PI, developing worsening heart failure and new onset TLS days after the administration of carfilzomib.
doi_str_mv 10.7759/cureus.33538
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9907735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780654537</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-9e57138db65372853008f6f02d5699c30f8c7d6c654c6cee6d865cd87da93d7a3</originalsourceid><addsrcrecordid>eNpVkdFPwjAQhxujEYK8-Wya-OqwW1nbvZgoESGBaCLGx6a0nRS3FduVBP96hyDBp7vkvtx9uR8AlzHqUZpmtzI4HXwP4xSzE9BOYsIiFrP-6VHfAl3vlwihGNEEUXQOWphQmsV93AafA-FyU3zb0syjcaWC1ArOQmkdnGy88fB1UylnSw1FpeCDWeuqdkaGQjg40sLVcChM0VhAU0EBX0RtGgK-m3oBp6GozarQcLrRhS3FBTjLReF1d1874G34OBuMosnz03hwP4lkQkgdZTqlMWZqTlJME5ZihFhOcpSolGSZxChnkioiSdqXRGpNFCOpVIwqkWFFBe6Au93eVZiXWsmtsij4yplSuA23wvD_k8os-Idd8yxDlDav7IDr_QJnv4L2NV_a4KrGmSeUoeZwY9ZQNztKOuu90_nhQoz4Nh2-S4f_ptPgV8dWB_gvC_wDHv-NyQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780654537</pqid></control><display><type>article</type><title>Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central</source><creator>Azad, Farhan ; Moyer, Ross ; Miranda, Clive J ; Gravina, Matthew</creator><creatorcontrib>Azad, Farhan ; Moyer, Ross ; Miranda, Clive J ; Gravina, Matthew</creatorcontrib><description>Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following the use of PIs in MM, a malignancy not known to cause TLS, has seldom been reported. We present a case of a patient with a known diagnosis of MM who received prior therapy including bortezomib, a first-generation PI, developing worsening heart failure and new onset TLS days after the administration of carfilzomib.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.33538</identifier><identifier>PMID: 36779143</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Blood tests ; Carbon dioxide ; Cardiology ; Case reports ; Chemotherapy ; Creatinine ; Ejection fraction ; Emergency medical care ; Heart failure ; Hemoglobin ; Inhibitor drugs ; Laboratories ; Medical prognosis ; Metabolism ; Multiple myeloma ; Oncology ; Patients ; Potassium ; Targeted cancer therapy ; Tomography ; Ultrasonic imaging</subject><ispartof>Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e33538</ispartof><rights>Copyright © 2023, Azad et al.</rights><rights>Copyright © 2023, Azad et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Azad et al. 2023 Azad et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-9e57138db65372853008f6f02d5699c30f8c7d6c654c6cee6d865cd87da93d7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2780654537/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2780654537?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36779143$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azad, Farhan</creatorcontrib><creatorcontrib>Moyer, Ross</creatorcontrib><creatorcontrib>Miranda, Clive J</creatorcontrib><creatorcontrib>Gravina, Matthew</creatorcontrib><title>Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following the use of PIs in MM, a malignancy not known to cause TLS, has seldom been reported. We present a case of a patient with a known diagnosis of MM who received prior therapy including bortezomib, a first-generation PI, developing worsening heart failure and new onset TLS days after the administration of carfilzomib.</description><subject>Blood tests</subject><subject>Carbon dioxide</subject><subject>Cardiology</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Creatinine</subject><subject>Ejection fraction</subject><subject>Emergency medical care</subject><subject>Heart failure</subject><subject>Hemoglobin</subject><subject>Inhibitor drugs</subject><subject>Laboratories</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Multiple myeloma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Potassium</subject><subject>Targeted cancer therapy</subject><subject>Tomography</subject><subject>Ultrasonic imaging</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpVkdFPwjAQhxujEYK8-Wya-OqwW1nbvZgoESGBaCLGx6a0nRS3FduVBP96hyDBp7vkvtx9uR8AlzHqUZpmtzI4HXwP4xSzE9BOYsIiFrP-6VHfAl3vlwihGNEEUXQOWphQmsV93AafA-FyU3zb0syjcaWC1ArOQmkdnGy88fB1UylnSw1FpeCDWeuqdkaGQjg40sLVcChM0VhAU0EBX0RtGgK-m3oBp6GozarQcLrRhS3FBTjLReF1d1874G34OBuMosnz03hwP4lkQkgdZTqlMWZqTlJME5ZihFhOcpSolGSZxChnkioiSdqXRGpNFCOpVIwqkWFFBe6Au93eVZiXWsmtsij4yplSuA23wvD_k8os-Idd8yxDlDav7IDr_QJnv4L2NV_a4KrGmSeUoeZwY9ZQNztKOuu90_nhQoz4Nh2-S4f_ptPgV8dWB_gvC_wDHv-NyQ</recordid><startdate>20230109</startdate><enddate>20230109</enddate><creator>Azad, Farhan</creator><creator>Moyer, Ross</creator><creator>Miranda, Clive J</creator><creator>Gravina, Matthew</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230109</creationdate><title>Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma</title><author>Azad, Farhan ; Moyer, Ross ; Miranda, Clive J ; Gravina, Matthew</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-9e57138db65372853008f6f02d5699c30f8c7d6c654c6cee6d865cd87da93d7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Blood tests</topic><topic>Carbon dioxide</topic><topic>Cardiology</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Creatinine</topic><topic>Ejection fraction</topic><topic>Emergency medical care</topic><topic>Heart failure</topic><topic>Hemoglobin</topic><topic>Inhibitor drugs</topic><topic>Laboratories</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Multiple myeloma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Potassium</topic><topic>Targeted cancer therapy</topic><topic>Tomography</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azad, Farhan</creatorcontrib><creatorcontrib>Moyer, Ross</creatorcontrib><creatorcontrib>Miranda, Clive J</creatorcontrib><creatorcontrib>Gravina, Matthew</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azad, Farhan</au><au>Moyer, Ross</au><au>Miranda, Clive J</au><au>Gravina, Matthew</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-01-09</date><risdate>2023</risdate><volume>15</volume><issue>1</issue><spage>e33538</spage><pages>e33538-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Carfilzomib is a proteasome inhibitor (PI) used in multiple myeloma (MM) that is resistant to other therapies. Despite its efficacy and potency, carfilzomib has been associated with kidney injuries, cardiovascular toxic effects, and hematological adverse events. Tumor lysis syndrome (TLS) following the use of PIs in MM, a malignancy not known to cause TLS, has seldom been reported. We present a case of a patient with a known diagnosis of MM who received prior therapy including bortezomib, a first-generation PI, developing worsening heart failure and new onset TLS days after the administration of carfilzomib.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36779143</pmid><doi>10.7759/cureus.33538</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2023-01, Vol.15 (1), p.e33538
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9907735
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central
subjects Blood tests
Carbon dioxide
Cardiology
Case reports
Chemotherapy
Creatinine
Ejection fraction
Emergency medical care
Heart failure
Hemoglobin
Inhibitor drugs
Laboratories
Medical prognosis
Metabolism
Multiple myeloma
Oncology
Patients
Potassium
Targeted cancer therapy
Tomography
Ultrasonic imaging
title Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A57%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carfilzomib-Induced%20Tumor%20Lysis%20Syndrome%20and%20Biventricular%20Heart%20Failure%20in%20a%20Patient%20With%20Multiple%20Myeloma&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Azad,%20Farhan&rft.date=2023-01-09&rft.volume=15&rft.issue=1&rft.spage=e33538&rft.pages=e33538-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.33538&rft_dat=%3Cproquest_pubme%3E2780654537%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-9e57138db65372853008f6f02d5699c30f8c7d6c654c6cee6d865cd87da93d7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2780654537&rft_id=info:pmid/36779143&rfr_iscdi=true